Sanofi gains first approval for nanobody-based medicine Cablivi

French pharma major Sanofi (Euronext: SAN) has been granted EU approval to market Cablivi (caplacizumab) for episodes of a rare and life-threatening genetic disorder, acquired thrombotic thrombocytopenic purpura (aTTP).

Cablivi, an anti-vWF nanobody, is the first product specifically indicated for the treatment of aTTP, and the company's first nanobody-based medicine to receive approval.

The current standard-of-care treatment, daily plasma exchange (PEX) and immunosuppression, is not enough to improve prevent mortality rates of up to 20%.